197A — TAUNS Laboratories Balance Sheet
0.000.00%
- ¥58bn
- ¥63bn
- ¥18bn
- 88
- 57
- 70
- 85
Annual balance sheet for TAUNS Laboratories, fiscal year end - June 30th, JPY millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | Yuho |
Standards: | JAS | JAS | JAS |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Cash and Short Term Investments | 6,347 | 1,244 | 9,425 |
Net Total Accounts Receivable | |||
Net Total Receivables | 942 | 3,481 | 2,723 |
Total Inventory | |||
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 12,036 | 9,457 | 16,916 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 3,683 | 4,402 | 7,905 |
Net Intangible Assets | |||
Long Term Investments | |||
Long Term Notes Receivable | |||
Other Long Term Assets | |||
Total Assets | 20,268 | 18,332 | 29,261 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Current Portion of Long Term Debt / Capital Leases | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 8,937 | 6,518 | 10,474 |
Long Term Debt | |||
Total Long Term Debt | |||
Total Debt | |||
Deferred Income Tax | |||
Total Other Liabilities | |||
Total Funded Status | |||
Total Liabilities | 12,912 | 9,842 | 15,595 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Unrealized Gain / Loss | |||
Other Equity | |||
Total Equity | 7,356 | 8,490 | 13,667 |
Total Liabilities & Shareholders' Equity | 20,268 | 18,332 | 29,261 |
Total Common Shares Outstanding |